Funding will support Ayana Bio's research examining the neuroprotective benefits of saffron for Huntington's Disease and other neurological and age-related diseases

资金将支持Ayana Bio的研究，研究藏红花对亨廷顿舞蹈病和其他神经系统疾病和年龄相关疾病的神经保护作用

BOSTON, May 1, 2024 /PRNewswire/ -- Ayana Bio, the plant cell technology company dedicated to creating sustainable bioactives for consumer products, has received a grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH), to support Ayana Bio's research into the production of saffron's neuroprotective bioactives through plant cell cultivation.

波士顿，2024年5月1日/PRNewswire/--致力于为消费品创造可持续生物活性的植物细胞技术公司Ayana Bio获得了美国国立卫生研究院（NIH）下属的国家补充与综合健康中心（NCCIH）的资助，以支持Ayana Bio通过植物细胞培养生产藏红花神经保护生物活性的研究。

.

.

Clinical studies demonstrate saffron's beneficial effects across a range of neurological and age-related diseases, such as depression, anxiety and Alzheimer's disease. Saffron's neurological effects are also proven to aid in weight loss by increasing satiety, making it a powerful health ingredient with interconnected benefits..

临床研究表明，藏红花对一系列神经系统疾病和与年龄有关的疾病，如抑郁症、焦虑症和阿尔茨海默氏病具有有益作用。藏红花的神经作用也被证明可以通过增加饱腹感来帮助减肥，使其成为一种强大的健康成分，具有相互关联的益处。。

The $300 thousand NIH grant will fund Ayana Bio's research to identify which complex of saffron bioactives can consistently demonstrate the highest neuroprotective benefits, specifically for Huntington's disease. The company will use its high-throughput synthetic biology capabilities of sequencing, multi-omics technology, and analytical chemistry to explore and select the best plant cell lines.

美国国立卫生研究院30万美元的拨款将资助Ayana Bio的研究，以确定哪种藏红花生物活性复合物可以始终如一地显示出最高的神经保护作用，特别是对亨廷顿舞蹈病。该公司将利用其测序，多组学技术和分析化学的高通量合成生物学能力来探索和选择最佳的植物细胞系。

The research will also address how plant cell cultivation can enhance the production of saffron's bioactives by running a pre-clinical study on a C. elegans model of Huntington's disease. Identifying a standardized complex of bioactives that can be produced consistently will allow researchers to study saffron's health benefits more effectively for a range of diseases..

这项研究还将通过对亨廷顿舞蹈病的秀丽隐杆线虫模型进行临床前研究，探讨植物细胞培养如何增强藏红花生物活性的产生。确定可以持续生产的标准化生物活性复合物将使研究人员能够更有效地研究藏红花对一系列疾病的健康益处。。

Plant cell cultivation is a means to create plant materials without growing plants in the ground. Saffron cells will be grown in temperature-controlled, stainless steel tanks that create a reliable source of real saffron – and its beneficial bioactive complex – bypassing the quality issues that come from the constraints of conventional agriculture.

植物细胞培养是一种不在地下种植植物而创造植物材料的手段。藏红花细胞将在温度可控的不锈钢罐中生长，从而为真正的藏红花及其有益的生物活性复合物提供可靠的来源，从而避免了传统农业限制带来的质量问题。

Traditional saffron production requires up to 170,000 flowers to produce just one kilo of saffron, making it a prohibitively expensive health and wellness ingredient. Challenges associated with growing saffron are amplified by the worsening effects of climate change, which drive crop failures in the already constrained supply chain..

传统的藏红花生产需要多达17万朵花才能生产出一公斤藏红花，这使得它成为一种昂贵的保健成分。气候变化的恶化影响加剧了与番红花种植相关的挑战，这导致了本已受限制的供应链中的作物歉收。。

'Saffron is a super ingredient for our brains—not just our taste buds—but it remains untapped due to its exorbitant cost,' said Frank Jaksch, CEO of Ayana Bio. 'Today's grant from the NIH is a validation of plant cell cultivation's ability to unlock botanicals like saffron's powerful benefits and improve health outcomes.'.

Ayana Bio首席执行官弗兰克·雅克施（Frank Jaksch）说：“藏红花不仅是味蕾，而且由于其高昂的成本，它仍然是大脑的超级成分。今天，美国国立卫生研究院（NIH）的拨款验证了植物细胞培养能够释放藏红花等植物药的强大功效，改善健康状况。”。

The NIH grant comes on the heels of Ayana Bio's joint development agreement with Wooree Bio to develop plant-cell derived saffron for health and wellness products in the South Korean market. For more information about Ayana Bio and their plant cell cultivation ingredients, please visit www.ayanabio.com..

美国国立卫生研究院拨款紧随Ayana Bio与Wooree Bio的联合开发协议而来，该协议旨在开发植物细胞衍生的藏红花，用于韩国市场的健康和保健产品。有关Ayana Bio及其植物细胞培养成分的更多信息，请访问www.ayanabio.com。。

This research is funded by the NCCIH and NIH under award number 1R43AT012848-01.

这项研究由NCCIH和NIH资助，奖项编号为1R43AT012848-01。

Disclaimer:The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

免责声明：内容完全由作者负责，不一定代表NIH的官方观点。

About Ayana BioAyana Bio uses plant cell cultivation to grow plant materials without growing them in the ground. Ayana Bio focuses on creating ingredients that leverage plant bioactives for health and wellness products. Plant cell-derived ingredients solve many of the sustainability, purity, safety and ethical concerns in current botanical supply chains.

关于Ayana BioAyana Bio使用植物细胞培养来生长植物材料，而不在地下生长。Ayana Bio专注于开发利用植物生物活性成分的健康保健产品。植物细胞衍生成分解决了当前植物供应链中的许多可持续性，纯度，安全性和道德问题。

Ayana Bio collaborates with global industry leaders in food, beverage, dietary supplement, sports nutrition, animal care and skin care to bring the power of plant bioactives to the mass market at scale. Ayana Bio has partnered with the global leader in synthetic biology, Ginkgo Bioworks, to select, optimize and scale plant cell-cultivated ingredients.

Ayana Bio与食品、饮料、膳食补充剂、运动营养、动物护理和皮肤护理领域的全球行业领导者合作，将植物生物活性物质的力量大规模推向大众市场。Ayana Bio与合成生物学领域的全球领导者银杏生物工程（Ginkgo Bioworks）合作，选择、优化和扩大植物细胞培养成分。

Ayana Bio is backed by prestigious investors, Viking Global and Cascade, to democratize nature's bioactives. For more information visit www.ayanabio.com..

Ayana Bio得到了著名投资者Viking Global和Cascade的支持，以使自然界的生物活性民主化。有关更多信息，请访问www.ayanabio.com。。

Media ContactsCassidy Torresayanabio@missionnorth.com

媒体联系人Torresayanabio@missionnorth.com

SOURCE Ayana Bio

来源Ayana Bio